Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
about
Gemcitabine for unresectable, locally advanced or metastatic bladder cancerRole of systemic chemotherapy in urothelial urinary bladder cancerPaclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen.Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.First- and second-line therapy for metastatic urothelial carcinoma of the bladderMetastatic bladder cancer: a review of current managementConditional Survival in de novo Metastatic Urothelial CarcinomaUse of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.Vinflunine in the treatment of advanced bladder cancer.Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.Chemotherapy for bladder cancer in patients with impaired renal function.Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review.The safety and efficacy of gemcitabine for the treatment of bladder cancer.Chemotherapy for Muscle-Invasive Bladder Cancer.Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).Vinflunine in the treatment of bladder cancer.Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.[Systemic therapy of metastatic bladder cancer.]Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
P2860
Q24235162-607EB0EF-518F-4273-A15A-CD7AF0088EFAQ27010323-4AB7249A-E071-4052-8547-769E2C7BA6D6Q33376440-E9525867-FF0D-40CA-B410-BDCA8258AC0EQ33394213-47BE30D8-A389-488A-9DA3-2799CAA85875Q33431220-8EFF1E8B-4789-4EAE-B00C-9D7183643367Q34541463-900D0F21-37D2-43C0-A1CD-F250BA9860FAQ35394211-E1BCC1DB-D8E2-4AC3-B1C0-872A40D70DF3Q35756105-3971BD87-10B2-4CF6-90E8-A69746D733E2Q36192053-CE92DDAE-BF35-4F7F-BEE9-F3618256CBD0Q36859124-2283EEF9-5A51-4BDA-8159-94ABEABEFD0DQ37284023-026E239B-2B5A-4522-ABF5-141E2EC9E13DQ37821892-F88D36D4-C4C3-46B5-BE0F-0FD08307DE3EQ37896172-58E153F6-9A0B-41D3-8A1B-6AF4AAAB061CQ37959263-CE4A28B7-3669-47CC-8DEE-1476719310AAQ38155201-8EAD616F-FF0D-496A-9B3F-13C88ECA19A2Q38181169-6C963E38-46B8-42FA-9B43-DAD51EB64013Q38701535-7F3D77D0-2BE3-45FE-A239-58F483B76FD8Q38711504-DE1D002D-CE1F-4CB5-940C-F88F6A1142D5Q38798645-4A21B0BA-25ED-47A9-8ED1-A0796C6FB707Q42183149-C536368F-2024-41E2-A846-0CCA0742E85AQ43654255-91569CC0-5EF0-4B68-9752-2C273E44E2F5Q44373064-E1BBE805-D81F-472A-B95E-A7B39ACD3E40Q44419809-DFB4CDDB-FCC4-4EB5-A3EC-370D22A6ED16Q46935351-0C5E8127-5762-43C7-8096-30527EE722DDQ53462584-E0915945-ED3B-4356-9B26-50D944B04B03
P2860
Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Randomised phase II trial of g ...... arcinoma (AUO Trial AB 20/99).
@ast
Randomised phase II trial of g ...... arcinoma (AUO Trial AB 20/99).
@en
type
label
Randomised phase II trial of g ...... arcinoma (AUO Trial AB 20/99).
@ast
Randomised phase II trial of g ...... arcinoma (AUO Trial AB 20/99).
@en
prefLabel
Randomised phase II trial of g ...... arcinoma (AUO Trial AB 20/99).
@ast
Randomised phase II trial of g ...... arcinoma (AUO Trial AB 20/99).
@en
P2093
P1476
Randomised phase II trial of g ...... arcinoma (AUO Trial AB 20/99).
@en
P2093
German Association Of Urologic Oncology (Auo) Bladder Cancer Study Group
P356
10.1111/J.1742-1241.2005.00663.X
P577
2006-01-01T00:00:00Z